From 4d9fb53f596af413861df08ee8ec0bd13b1696e4 Mon Sep 17 00:00:00 2001
From: Teleo Agents <agents@livingip.xyz>
Date: Tue, 7 Apr 2026 01:10:24 +0000
Subject: [PATCH] reweave: connect 19 orphan claims via vector similarity

Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
---
 ...g-ottawa-treaty-path-for-medium-utility-categories.md | 2 ++
 ...es-portfolio-hedge-strategy-for-bifurcated-markets.md | 4 ++++
 ...yment-requirements-and-no-post-market-surveillance.md | 2 ++
 ...income-levels-indicating-structural-system-failure.md | 4 ++++
 ...ife-expectancy-plateau-3-11x-more-than-drug-deaths.md | 4 ++++
 ...to-adverse-events-due-to-structural-reporting-gaps.md | 2 ++
 ...systematic-under-detection-of-ai-attributable-harm.md | 2 ++
 ...ome-users-despite-nominal-technology-access-equity.md | 4 ++++
 ...d introduce errors when overriding correct outputs.md | 4 ++++
 ...condary-to-primary-cvd-mortality-driver-since-2022.md | 2 ++
 ...eate-global-access-pathway-before-us-patent-expiry.md | 4 ++++
 ...ency-not-safety-creating-accidental-harm-reduction.md | 4 ++++
 ...t-65x-while-maintaining-performance-under-workload.md | 4 ++++
 ...active-harm-accumulation-not-after-safety-evidence.md | 9 +++++++++
 ...sk-oversight-despite-accumulating-failure-evidence.md | 5 +++++
 ...lation-creating-institutional-epistemic-divergence.md | 4 ++++
 ...ulation-converged-on-adoption-acceleration-q1-2026.md | 7 +++++++
 ...-hypertension-through-chronic-inflammation-pathway.md | 4 ++++
 ...tion-explaining-antihypertensive-treatment-failure.md | 4 ++++
 ...mic-declining-heart-failure-hypertension-worsening.md | 4 ++++
 ...cess-and-equity-failures-override-clinical-quality.md | 4 ++++
 ...lining-while-lifespan-recovers-creating-divergence.md | 4 ++++
 ...span-gap-largest-globally-despite-highest-spending.md | 4 ++++
 ...ls-sbsp-credibility-as-climate-technology-category.md | 4 ++++
 ...a void that 4 companies are racing to fill by 2030.md | 3 +++
 ...ture-requirements-creating-dual-use-revenue-bridge.md | 4 ++++
 ...ndent-on-nasa-capital-for-manufacturing-transition.md | 4 ++++
 ...-to-commercial-space-timelines-as-technical-delays.md | 4 ++++
 ...odc-the-near-term-revenue-bridge-to-long-term-sbsp.md | 4 ++++
 .../uk-house-of-lords-science-technology-committee.md    | 4 ++++
 30 files changed, 118 insertions(+)

diff --git a/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md b/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md
index f3abe5e21..f6dad7218 100644
--- a/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md
+++ b/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md
@@ -14,8 +14,10 @@ attribution:
 related: ["the legislative ceiling on military ai governance is conditional not absolute cwc proves binding governance without carveouts is achievable but requires three currently absent conditions"]
 supports:
 - Binding international AI governance achieves legal form through scope stratification — the Council of Europe AI Framework Convention entered force by explicitly excluding national security, defense applications, and making private sector obligations optional
+- Ottawa model treaty process cannot replicate for dual-use AI systems because verification architecture requires technical capability inspection not production records
 reweave_edges:
 - Binding international AI governance achieves legal form through scope stratification — the Council of Europe AI Framework Convention entered force by explicitly excluding national security, defense applications, and making private sector obligations optional|supports|2026-04-04
+- Ottawa model treaty process cannot replicate for dual-use AI systems because verification architecture requires technical capability inspection not production records|supports|2026-04-07
 ---
 
 # AI weapons governance tractability stratifies by strategic utility — high-utility targeting AI faces firm legislative ceiling while medium-utility loitering munitions and autonomous naval mines follow Ottawa Treaty path where stigmatization plus low strategic exclusivity enables binding instruments outside CCW
diff --git a/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md b/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md
index 3b9fe1dda..b9694acc9 100644
--- a/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md
+++ b/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md
@@ -10,6 +10,10 @@ agent: vida
 scope: functional
 sourcer: Medical Dialogues
 related_claims: ["[[tirzepatide-patent-thicket-extends-exclusivity-to-2041-bifurcating-glp1-market-into-commodity-and-premium-tiers]]"]
+supports:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
+reweave_edges:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036|supports|2026-04-07
 ---
 
 # Cipla's dual role as generic semaglutide entrant AND Lilly's branded tirzepatide partner exemplifies the portfolio hedge strategy for pharmaceutical companies navigating market bifurcation
diff --git a/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md b/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md
index 10a99e0fc..a04eb6279 100644
--- a/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md
+++ b/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md
@@ -13,9 +13,11 @@ related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because
 supports:
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 reweave_edges:
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality|supports|2026-04-07
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events|supports|2026-04-07
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities|supports|2026-04-07
 ---
 
 # The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
diff --git a/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md b/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md
index 9a45d4c15..3b225e301 100644
--- a/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md
+++ b/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md
@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: Leah Abrams, Neil Mehta
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+related:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
+reweave_edges:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|related|2026-04-07
 ---
 
 # CVD mortality stagnation after 2010 affects all income levels including the wealthiest counties indicating structural system failure not poverty correlation
diff --git a/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md b/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md
index 61d93d911..ec89374ac 100644
--- a/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md
+++ b/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md
@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: Shiels MS, Chernyavskiy P, Anderson WF, et al. (NCI)
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
+supports:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
+reweave_edges:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
 ---
 
 # CVD mortality stagnation drives US life expectancy plateau 3-11x more than drug deaths inverting the dominant opioid crisis narrative
diff --git a/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md b/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
index ee3f5e3be..840fdb75d 100644
--- a/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
+++ b/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
@@ -13,9 +13,11 @@ related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because
 supports:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm"}
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
 reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07"}
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events|supports|2026-04-07
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07
 ---
 
 # FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
diff --git a/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md b/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
index 907320fce..21fc7eacd 100644
--- a/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
+++ b/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
@@ -13,9 +13,11 @@ related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alon
 supports:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm"}
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
 reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07"}
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality|supports|2026-04-07
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07
 ---
 
 # FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
diff --git a/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md b/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md
index 7fa4f3abb..8678edfe3 100644
--- a/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md
+++ b/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md
@@ -11,6 +11,10 @@ attribution:
   sourcer:
     - handle: "adepoju-et-al."
       context: "Adepoju et al. 2024, PMC11450565"
+related:
+- Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment
+reweave_edges:
+- Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment|related|2026-04-07
 ---
 
 # Generic digital health deployment reproduces existing disparities by disproportionately benefiting higher-income, higher-education users despite nominal technology access equity, because health literacy and navigation barriers concentrate digital health benefits upward
diff --git a/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md b/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md
index e36644098..81abf0468 100644
--- a/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md	
+++ b/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md	
@@ -5,6 +5,10 @@ domain: health
 created: 2026-02-18
 source: "DJ Patil interviewing Bob Wachter, Commonwealth Club, February 9 2026; Stanford/Harvard diagnostic accuracy study; European colonoscopy AI de-skilling study"
 confidence: likely
+supports:
+- NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning
+reweave_edges:
+- NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning|supports|2026-04-07
 ---
 
 # human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs
diff --git a/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md b/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md
index 9d3311b55..b491d94ed 100644
--- a/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md
+++ b/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md
@@ -12,8 +12,10 @@ sourcer: American Heart Association
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
 supports:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
 reweave_edges:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
 ---
 
 # Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
diff --git a/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md b/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md
index 3800de2dc..6eb77abf5 100644
--- a/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md
+++ b/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md
@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: Bloomberg / KFF Health News / BW Healthcare World
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+related:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
+reweave_edges:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036|related|2026-04-07
 ---
 
 # Indian generic semaglutide exports enabled by evergreening rejection create a global access pathway before US patent expiry
diff --git a/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md b/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md
index 6e508a8c0..1edb750ba 100644
--- a/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md
+++ b/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md
@@ -10,6 +10,10 @@ agent: vida
 scope: functional
 sourcer: Comparative analysis
 related_claims: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone", "healthcare-AI-regulation-needs-blank-sheet-redesign"]
+related:
+- Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload
+reweave_edges:
+- Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload|related|2026-04-07
 ---
 
 # Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption
diff --git a/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md b/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md
index ca3a14d6e..2d9df339f 100644
--- a/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md
+++ b/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md
@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: Girish N. Nadkarni, Mount Sinai
 related_claims: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone"]
+supports:
+- Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption
+reweave_edges:
+- Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption|supports|2026-04-07
 ---
 
 # Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload
diff --git a/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md b/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
index 53576fbd6..0f7dc2557 100644
--- a/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
+++ b/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
@@ -14,10 +14,19 @@ supports:
 - Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years
 - FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm"}
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 reweave_edges:
 - Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years|supports|2026-04-03
 - FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance|supports|2026-04-03
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07"}
+- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities|supports|2026-04-07
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
+related:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
 ---
 
 # Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
diff --git a/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md b/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
index 2d06894d9..61ba2a1e6 100644
--- a/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
+++ b/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
@@ -12,8 +12,13 @@ sourcer: Petrie-Flom Center, Harvard Law School
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]", "[[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]]"]
 supports:
 - EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 reweave_edges:
 - EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight|supports|2026-04-07
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities|supports|2026-04-07
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
+related:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
 ---
 
 # Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
diff --git a/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md b/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md
index d626954de..1b77579e4 100644
--- a/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md
+++ b/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md
@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: Health Policy Watch
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
+supports:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
+reweave_edges:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07
 ---
 
 # Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
diff --git a/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md b/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md
index 16b000720..ee46f3f7c 100644
--- a/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md
+++ b/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md
@@ -10,6 +10,13 @@ agent: vida
 scope: structural
 sourcer: UK House of Lords Science and Technology Committee
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
+related:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
+reweave_edges:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|related|2026-04-07
+- UK House of Lords Science and Technology Committee|supports|2026-04-07
+supports:
+- UK House of Lords Science and Technology Committee
 ---
 
 # All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
diff --git a/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md b/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md
index 7561a6b10..7bc0b26a0 100644
--- a/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md
+++ b/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md
@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: American Heart Association (REGARDS investigators)
 related_claims: ["[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
+supports:
+- Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
+reweave_edges:
+- Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control|supports|2026-04-07
 ---
 
 # Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
diff --git a/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md b/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md
index 6dce12c37..aedd17e46 100644
--- a/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md
+++ b/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md
@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: American Heart Association (REGARDS investigators)
 related_claims: ["[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+supports:
+- Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
+reweave_edges:
+- Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate|supports|2026-04-07
 ---
 
 # Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
diff --git a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
index 7f153c3e5..8650ddfec 100644
--- a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
+++ b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
@@ -12,8 +12,12 @@ sourcer: American Heart Association
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]]"]
 supports:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
 reweave_edges:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
 ---
 
 # US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
diff --git a/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md b/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md
index c97e9b3b9..c08226a5c 100644
--- a/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md
+++ b/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md
@@ -5,6 +5,10 @@ description: "Commonwealth Fund's 2024 international comparison shows US last ov
 confidence: proven
 source: "Commonwealth Fund Mirror Mirror 2024 report (Blumenthal et al, 2024-09-19)"
 created: 2026-03-11
+supports:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
 ---
 
 # US healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
diff --git a/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md b/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md
index a8d99ece0..05410933a 100644
--- a/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md
+++ b/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md
@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: WHO/JAMA 2024
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+supports:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
 ---
 
 # US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
diff --git a/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md b/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md
index e95739ecd..443874e1c 100644
--- a/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md
+++ b/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md
@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: Garmany et al. (Mayo Clinic)
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
+supports:
+- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
+reweave_edges:
+- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics|supports|2026-04-07
 ---
 
 # The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
diff --git a/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md b/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
index eaacbf94a..08298a931 100644
--- a/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
+++ b/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
@@ -10,6 +10,10 @@ agent: astra
 scope: functional
 sourcer: Data Center Dynamics / PRNewswire
 related_claims: ["[[power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited]]"]
+supports:
+- Aetherflux
+reweave_edges:
+- Aetherflux|supports|2026-04-07
 ---
 
 # Breakthrough Energy Ventures' investment in Aetherflux's orbital solar infrastructure signals that space-based solar power has achieved credibility as a climate technology investment category at institutional investor level
diff --git a/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md b/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md
index 849609c9a..16054729c 100644
--- a/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md	
+++ b/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md	
@@ -11,6 +11,9 @@ supports:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|related|2026-04-07
+related:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
 ---
 
 # commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
diff --git a/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md b/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
index 03e258ede..c519b904b 100644
--- a/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
+++ b/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
@@ -10,6 +10,10 @@ agent: astra
 scope: structural
 sourcer: Data Center Dynamics / The Register / Space.com
 related_claims: ["[[power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited]]", "[[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]"]
+supports:
+- Aetherflux
+reweave_edges:
+- Aetherflux|supports|2026-04-07
 ---
 
 # Orbital data centers and space-based solar power share identical infrastructure requirements in sun-synchronous orbit creating a dual-use architecture where near-term compute revenue cross-subsidizes long-term energy transmission development
diff --git a/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md b/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md
index 32b72daff..b80419ba8 100644
--- a/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md
+++ b/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md
@@ -10,6 +10,10 @@ agent: astra
 scope: causal
 sourcer: Mike Turner, Exterra JSC
 related_claims: ["[[commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"]
+supports:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
+reweave_edges:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|supports|2026-04-07
 ---
 
 # NASA CLD Phase 2 funding freeze creates existential risk for design-phase programs that lack private capital to self-fund manufacturing transition
diff --git a/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md b/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md
index 21880ceb7..d9030c2dc 100644
--- a/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md
+++ b/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md
@@ -10,6 +10,10 @@ agent: astra
 scope: causal
 sourcer: SpaceNews
 related_claims: ["[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]", "[[designing coordination rules is categorically different from designing coordination outcomes as nine intellectual traditions independently confirm]]"]
+supports:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
+reweave_edges:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|supports|2026-04-07
 ---
 
 # Policy-driven funding freezes can be as damaging to commercial space program timelines as technical delays because they create capital formation uncertainty
diff --git a/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md b/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md
index c307d4a19..7bef66221 100644
--- a/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md
+++ b/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md
@@ -10,6 +10,10 @@ agent: astra
 scope: structural
 sourcer: TechCrunch / Aetherflux
 related_claims: ["[[the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure]]", "[[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]", "[[power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited]]"]
+supports:
+- Aetherflux
+reweave_edges:
+- Aetherflux|supports|2026-04-07
 ---
 
 # Space-based solar power and orbital data centers share infrastructure making ODC the near-term revenue bridge to long-term SBSP
diff --git a/entities/health/uk-house-of-lords-science-technology-committee.md b/entities/health/uk-house-of-lords-science-technology-committee.md
index 799ea7934..6256214ce 100644
--- a/entities/health/uk-house-of-lords-science-technology-committee.md
+++ b/entities/health/uk-house-of-lords-science-technology-committee.md
@@ -6,6 +6,10 @@ domain: health
 founded: N/A
 status: active
 headquarters: London, UK
+related:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
+reweave_edges:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
 ---
 
 # UK House of Lords Science and Technology Committee